109
Views
8
CrossRef citations to date
0
Altmetric
Original Research

Efficacy of Venetoclax Combined with Decitabine-Based Treatment for Heavily Pre-Treated Relapsed or Refractory AML Patients in a Real-World Setting

ORCID Icon, , , , , ORCID Icon, , , & show all
Pages 5613-5621 | Published online: 12 Jul 2021

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Xing-yu Cao, Jia-qi Chen, Hui Wang, Wei Ma, Wei-wei Liu, Fang-fang Zhang, Song Xue, Lei Dong, Ting Liu, Xiao-zhen Zhao, Chan-chan Liu, Xin Xu, Yang He, Lei Wang & Jian-ling Wang. (2023) Addition of venetoclax to myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in high-risk AML. Annals of Medicine 55:1, pages 388-400.
Read now

Articles from other publishers (7)

Mengci Hu, Wenzhe Li, Youshan Zhang, Caixia Liang, Jie Tan & Ya Wang. (2023) Venetoclax in adult acute myeloid leukemia. Biomedicine & Pharmacotherapy 168, pages 115820.
Crossref
Xinhui Zheng, Hongye Gao, Ni Lu, Mingyang Wang, Haixiao Zhang, Yawei Zheng, Biao Shen, Yigeng Cao, Xin Chen, Weihua Zhai, Jialin Wei, Donglin Yang, Rongli Zhang, Aiming Pang, Sizhou Feng, Erlie Jiang & Mingzhe Han. (2023) Efficacy of venetoclax combined with decitabine conditioning regimen for allogeneic hematopoietic stem cell transplantation in high-risk and elderly patients with myeloid neoplasms. Annals of Hematology 102:12, pages 3603-3611.
Crossref
Nina Rosa Neuendorff, Nico Gagelmann, Surbhi Singhal, Shelby Meckstroth, Vincent Thibaud, Yue Zhao, Nabiel Mir, Yung-Yu Shih, Danielle M.C. Amaro, Mukul Roy, Joseph Lombardo, Lars Klingen Gjærde & Kah Poh Loh. (2023) Hypomethylating agent-based therapies in older adults with acute myeloid leukemia – A joint review by the Young International Society of Geriatric Oncology and European Society for Blood and Marrow Transplantation Trainee Committee. Journal of Geriatric Oncology 14:3, pages 101406.
Crossref
Yang Yang, Yamin Shu, Guosong Chen, Yanchao Yin, Feie Li & Juan Li. (2022) A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for venetoclax. PLOS ONE 17:12, pages e0278725.
Crossref
Rong Wang, Pan Xu, Lin-Lin Chang, Shi-Zhong Zhang & Hong-Hu Zhu. (2022) Targeted therapy in NPM1-mutated AML: Knowns and unknowns. Frontiers in Oncology 12.
Crossref
. (2022) Decitabine/venetoclax. Reactions Weekly 1911:1, pages 170-170.
Crossref
Serena Brancati, Lucia Gozzo, Giovanni Luca Romano, Calogero Vetro, Ilaria Dulcamare, Cinzia Maugeri, Marina Parisi, Laura Longo, Daniela Cristina Vitale, Francesco Di Raimondo & Filippo Drago. (2021) Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Are Supporting Evidences Enough?. Cancers 14:1, pages 22.
Crossref